Cargando…

Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma

BACKGROUND: Lenalidomide is an active immunomodulatory and antiproliferative agent in multiple myeloma. However, the molecular mechanisms driving these activities are not yet fully elucidated. Therefore, we investigated the modulation of the cytokine/growth factor patterns of myeloma cells under LEN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maïga, S, Gomez-Bougie, P, Bonnaud, S, Gratas, C, Moreau, P, Le Gouill, S, Pellat-Deceunynck, C, Amiot, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658519/ https://www.ncbi.nlm.nih.gov/pubmed/23632478 http://dx.doi.org/10.1038/bjc.2013.186

Ejemplares similares

The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction
por: Descamps, G, et al.
Publicado: (2012)

BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma
por: Bodet, L, et al.
Publicado: (2010)

Combination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of BIK
por: Brosseau, C, et al.
Publicado: (2014)

Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells
por: Chiron, D, et al.
Publicado: (2013)

Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways
por: Tessoulin, Benoît, et al.
Publicado: (2018)

Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups
por: Gomez-Bougie, Patricia, et al.
Publicado: (2014)

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
por: Touzeau, C, et al.
Publicado: (2014)

RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53(abnormal) myeloma cells independently of the p53 pathway
por: Surget, Sylvanie, et al.
Publicado: (2014)

Lack of BRAF V600E mutation in human myeloma cell lines established from myeloma patients with extramedullary disease
por: Lodé, L, et al.
Publicado: (2013)

Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma
por: Kervoëlen, Charlotte, et al.
Publicado: (2015)

Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes
por: Seiller, Carolane, et al.
Publicado: (2020)

Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells
por: Gillardin, Pierre-Samuel, et al.
Publicado: (2017)

Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma
por: Chiron, David, et al.
Publicado: (2015)

Dichloroacetate inhibits aerobic glycolysis in multiple myeloma cells and increases sensitivity to bortezomib
por: Sanchez, W Y, et al.
Publicado: (2013)

The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma
por: Benaniba, Lina, et al.
Publicado: (2019)

Differential downregulation of telomerase activity by bortezomib in multiple myeloma cells-multiple regulatory pathways in vitro and ex vivo
por: Weiss, C, et al.
Publicado: (2012)

BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival
por: Champion, Ophélie, et al.
Publicado: (2023)

PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells
por: Maginn, E N, et al.
Publicado: (2011)

Antitumour and antiangiogenic effects of Aplidin® in the 5TMM syngeneic models of multiple myeloma
por: Caers, J, et al.
Publicado: (2008)

Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells
por: Amit-Vazina, M, et al.
Publicado: (2005)

Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma
por: Cheriyath, V, et al.
Publicado: (2011)

Rapid in vivo testing of drug response in multiple myeloma made possible by xenograft to turkey embryos
por: Farnoushi, Y, et al.
Publicado: (2011)

Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo
por: Zhou, Liang, et al.
Publicado: (2018)

Apoptotic Machinery Diversity in Multiple Myeloma Molecular Subtypes
por: Gomez-Bougie, Patricia, et al.
Publicado: (2013)

An anti-leishmanial thiadiazine agent induces multiple myeloma cell apoptosis by suppressing the nuclear factor kappaB signalling pathway
por: Chen, G, et al.
Publicado: (2014)

BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy Biomarker
por: Tessoulin, Benoît, et al.
Publicado: (2019)

NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells
por: Di Matteo, P, et al.
Publicado: (2013)

Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents
por: Saha, M N, et al.
Publicado: (2014)

Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas
por: Salnikov, A V, et al.
Publicado: (2013)

Targeting Oxidative Stress With Auranofin or Prima-1(Met) to Circumvent p53 or Bax/Bak Deficiency in Myeloma Cells
por: Tessoulin, Benoit, et al.
Publicado: (2019)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

Manipulating the expression of chemokine receptors enhances delivery and activity of cytokine-induced killer cells
por: Zou, Y, et al.
Publicado: (2014)

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors
por: Moreaux, J, et al.
Publicado: (2013)

Multiple mechanisms underlie defective recognition of melanoma cells cultured in three-dimensional architectures by antigen-specific cytotoxic T lymphocytes
por: Feder-Mengus, C, et al.
Publicado: (2007)

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours
por: Zurita, A J, et al.
Publicado: (2015)

γ-Tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signalling pathways
por: Yap, W N, et al.
Publicado: (2008)

Sigma-2 ligands induce tumour cell death by multiple signalling pathways
por: Zeng, C, et al.
Publicado: (2012)

Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array
por: Perez-Gracia, J L, et al.
Publicado: (2009)

Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours
por: Zhang, X, et al.
Publicado: (2014)

A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45
por: Descamps, G, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_125rf6fbc1375cr92noo5klrum